health canada approval zepbound tirzepatide obesity canada 2024 2025 has approved Wegovy® (semaglutide) for the treatment of MASH (non-cirrhotic metabolic dysfunction-associated steatohepatitis) — a serious liver disease that is one of many downstream conditions related to obesity. As many Zepbound (Tirzepatide) | Uses &

has been paid by AJNA Labs, Journey Colab and Bright Minds Biosciences for advisory board participation

Semaglutide may be suitable for you if: Your body mass index (BMI) is 27 or higher with related health conditions or 30 and above without related conditions

Earlier this year, my colleague Yasmin Tayag wrote that Ozempicthe diabetes drug that has become a cultural phenomenon in its off-label use for weight-losswas about to be old news

Why does that make sense

Through a collaborative consultation, we help you explore options like Semaglutide or Tirzepatide, guiding you to the perfect solution for sustainable, healthy weight loss.